[Breast Cancer: Targets and Therapy] This review examines the characteristics of cancer genome, cancer genetics, and cancer epigenetic, and focuses on discussing both genetic and nongenetic factors responsible for the predisposition of breast cancer in humans.
Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.
Investigators conducted a case-control study of 3030 pancreatic cancer patients in an attempt to confirm which genes might render patients susceptible to pancreatic cancer.
Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.
Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
